Business Wire

Concert Pharmaceuticals Presents CTP-543 Data from Long-Term Extension Study in Alopecia Areata During Late-Breaking Session at EADV Congress

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented initial data from the ongoing long-term, open-label extension study of the investigational medicine ...
Business Wire

Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2 nd JAK Inhibitors Drug Development Summit

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today will present an update from its ongoing open label, long-term extension study of the investigational medicine ...
Monthly Prescribing Reference

Phase 1b study of CTP-518 for HIV

Concert Pharmaceuticals announced that it has initiated a Phase 1b clinical study with CTP-518, its investigational oral protease inhibitor for the treatment of HIV infection. Participants in this ...
Nasdaq

Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2nd JAK Inhibitors Drug Development Summit

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today will present an update from its ongoing open label, long-term extension study of the investigational medicine CTP ...